Publication | Open Access
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
382
Citations
40
References
2014
Year
ImmunologyImmune RegulationCell DeathImmunotherapeuticsImmunotherapyTumor BiologyCancer-associated VirusEbv-driven Lmp1Epstein-barr VirusTumor ImmunityNpc PatientsRadiation OncologyCell SignalingMolecular OncologyPd-l1 ExpressionMedicineImmune SurveillanceCell BiologyIfn-γ Up-regulate Pd-l1Cancer ImmunosurveillanceImmune Checkpoint InhibitorOncologyViral OncologyViral ImmunityOncotargeted Therapy
PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1